Target intelligence / Profile preview

Histone deacetylase complex subunit SAP30 (SAP30)

Target
SAP30
Molecular classification
Chromatin-associated protein, Histone modification complex subunit, Cofactor/corepressor, Transcription regulation complex component
01

Overview

Histone deacetylase complex subunit SAP30 (SAP30) is a core component of the SIN3/HDAC histone deacetylase complex, acting as a scaffold that recruits the complex to specific genomic loci, thereby mediating transcriptional repression through histone deacetylation[1][2][3][4][5][6][7]. SAP30 interacts with key partners such as SIN3A, HDAC1, HDAC2, RbAp46/48, and others, influencing chromatin structure and gene expression. It can bind DNA and is regulated by nuclear phosphoinositides. In human cancers, including clear cell renal cell carcinoma, SAP30 is implicated in tumor proliferation and apoptosis—partly via repression of MT1G and p53 activity—making it a potential therapeutic and prognostic target[4]. No drugs are known to directly target SAP30, but it is essential for the function of HDAC complexes, which are therapeutically targeted in oncology and other diseases.

Other names
Sin3A-associated protein, 30 kDaSin3 corepressor complex subunit SAP3030 kDa Sin3-associated polypeptideSin3-associated polypeptide p30Sin3-associated polypeptide, 30 kDaSAP30
02

Mechanism of action

When part of an HDAC complex, inhibition by HDAC inhibitors leads to increased histone acetylation and de-represssion of gene expression; SAP30 mediates recruitment of HDAC activity to specific gene loci.

03

Biological functions

Epigenetic gene regulationTranscriptional repressionRegulation of histone acetylation and deacetylationDNA bindingChromatin remodelingCell cycle regulationApoptosis
04

Disease associations

CancerRenal cell carcinomaPotential roles in other tumor types (by analogy with its general corepressor functions)
05

Safety considerations

No SAP30-specific safety concerns reportedChromatin-modifying complex inhibitors can cause broad effects on gene expression, leading to potential hematologic, hepatic, or developmental toxicities (based on HDAC inhibitor class, not SAP30-specific risks)
06

Interacting drugs

Vorinostat (indirectly, as a component of the HDAC complex)

1 more in the full profile.

07

Biomarkers

SAP30 expression (prognostic marker in clear cell renal cell carcinoma)SAP30-regulated MT1G and p53 (potential downstream effectors/biomarkers in cancer)

Beyond the preview

Go deeper on Histone deacetylase complex subunit SAP30 (SAP30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone deacetylase complex subunit SAP30 (SAP30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call